Suppr超能文献

降低经皮左心室辅助装置支持的高危经皮冠状动脉介入治疗血管和出血风险的策略

Strategies for Reducing Vascular and Bleeding Risk for Percutaneous Left Ventricular Assist Device-supported High-risk Percutaneous Coronary Intervention.

作者信息

Vetrovec George W, Kaki Amir, Wollmuth Jason, Dahle Thom G

机构信息

VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA.

Division of Cardiology, St. John's Hospital, Wayne State University, Detroit, MI, USA.

出版信息

Heart Int. 2022 Dec 21;16(2):105-111. doi: 10.17925/HI.2022.16.2.105. eCollection 2022.

Abstract

In patients at high risk for haemodynamic instability during percutaneous coronary intervention (PCI), practitioners are increasingly opting for prophylactic mechanical circulatory support, such as the Impella® heart pump (Abiomed, Danvers, MA, USA). Though Impella-supported high-risk PCI (HRPCI) ensures haemodynamic stability during the PCI procedure, access-related complication rates have varied significantly in published studies. Reported variability in complication rates relates to many factors, including anticoagulation practices, access and closure strategy, post-procedure care and variations in event definitions. This article aims to outline optimal strategies to minimize vascular and bleeding complications during Impella-supported HRPCI based on previously identified clinical, procedural and postprocedural risk factors. Practices to reduce complications include femoral skills training, standardized protocols to optimize access, closure, anticoagulation management and post-procedural care, as well as the application of techniques and technological advances. Protocols integrating these strategies to mitigate access-related bleeding and vascular complications for Impella-supported procedures can markedly limit vascular access risk as a barrier to appropriate large-bore mechanical circulatory support use in HRPCI.

摘要

在经皮冠状动脉介入治疗(PCI)期间存在血流动力学不稳定高风险的患者中,医生越来越倾向于选择预防性机械循环支持,如Impella®心脏泵(美国马萨诸塞州丹弗斯市的Abiomed公司生产)。尽管Impella支持的高风险PCI(HRPCI)可确保PCI手术期间的血流动力学稳定,但在已发表的研究中,与通路相关的并发症发生率差异很大。报道的并发症发生率差异与许多因素有关,包括抗凝措施、通路和闭合策略、术后护理以及事件定义的差异。本文旨在根据先前确定的临床、手术和术后风险因素,概述在Impella支持的HRPCI期间将血管和出血并发症降至最低的最佳策略。减少并发症的做法包括股动脉技术培训、优化通路、闭合、抗凝管理和术后护理的标准化方案,以及技术和工艺进步的应用。将这些策略整合到协议中,以减轻Impella支持手术中与通路相关的出血和血管并发症,可显著降低血管通路风险,而这种风险是在HRPCI中合理使用大口径机械循环支持的障碍。

相似文献

3
Percutaneous Transvalvular Microaxial Flow Pump Support in Cardiology.经皮跨瓣微轴流泵支持在心脏病学中的应用。
Circulation. 2022 Apr 19;145(16):1254-1284. doi: 10.1161/CIRCULATIONAHA.121.058229. Epub 2022 Apr 18.
4
The role of Impella in high-risk percutaneous coronary intervention.Impella在高危经皮冠状动脉介入治疗中的作用。
Rev Port Cardiol (Engl Ed). 2018 Jul;37(7):623.e1-623.e4. doi: 10.1016/j.repc.2017.05.013. Epub 2018 May 26.
10
A Review of the Impella Devices.Impella设备综述
Interv Cardiol. 2022 Apr 8;17:e05. doi: 10.15420/icr.2021.11. eCollection 2022 Jan.

引用本文的文献

本文引用的文献

9
Managing vascular access and closure for percutaneous mechanical circulatory support.经皮机械循环支持的血管通路管理与闭合
Eur Heart J Suppl. 2021 Mar 27;23(Suppl A):A10-A14. doi: 10.1093/eurheartj/suab002. eCollection 2021 Mar.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验